- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07544420
Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy (AKL003)
An Open-Label, Single-Arm Phase I Trial to Evaluate the Safety, Tolerability, and Serum Alpha-Klotho Protein Expression Following a Single Administration of Alpha Klotho mRNA (aKLmRNA), AKL003
This is an open-label, single-arm, single-site Phase I trial in a total of 20 healthy participants at GARM Próspera, Roatán, Honduras. Each participant receives one intravenous administration of 0.5 mg AKL003 on Day 0.
Screening is followed by one treatment visit at GARM Próspera covering Day -1 to Day 2. Scheduled follow-up comprises Day 7 and the actual remote Final Visit (nominal Day 28 ±7 days), following local assessments under Investigator oversight.
Safety is assessed through adverse events, clinical examinations, vital signs, ECG and laboratory testing. Six months of passive safety follow-up after the individual Final Visit or Early Termination Visit.
PsyTool, QoL, Oura and DNA methylation assessments are retained. Exploratory changes do not establish clinical efficacy without a concurrent control group.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is an open-label, single-arm, single-site Phase I trial evaluating safety, tolerability and serum alpha-Klotho protein expression after a single intravenous administration of AKL003, a proprietary alpha-Klotho mRNA formulated in lipid nanoparticles. Twenty participants in total will receive AKL003 at GARM Próspera, Roatán, Honduras.
Each participant will receive one 0.5 mg intravenous administration on Day 0. Screening and later laboratory follow-up may be conducted through designated providers in the USA under the responsible Investigator's oversight. One treatment visit at GARM Próspera, Roatán, Honduras is required, covering Day -1 through Day 2. Scheduled follow-up comprises Day 7 and the actual remote Final Visit (nominal Day 28 ±7 days), following local laboratory and physical assessments. All participants follow the protocol-defined eligibility criteria, dose, pre- and post-treatment dexamethasone regimen, assessment schedule and safety procedures.
Systemic reactogenicity events, including fever, headache, myalgia, fatigue, nausea/vomiting, diarrhea and increased heart rate, will be assessed as adverse events. Severity will be graded ; CRS will be graded according to ASTCT criteria where applicable.
All participants will be informed about potential clinical activity and reactogenicity, which may be influenced by increased aKL serum levels or the lipid nanoparticle formulation. Participants will be instructed to contact the trial site to schedule an on-site visit in case of any unexpected adverse event (unscheduled visit,). All such occurrences will be documented as part of the drug candidate's safety evaluation.
Participants will use an electronic diary for daily symptoms through Day 7 and report new or worsening symptoms promptly throughout follow-up. Quality-of-life questionnaires will be completed at baseline and weekly during follow-up, including the actual Final Visit. Oura-derived measures will be collected from screening through the actual Final Visit. PsyTool assessments and other exploratory measures will be collected at different timepoints.
After the individual Final Visit or Early Termination Visit, safety information received during six months of passive follow-up will be assessed. This period adds no scheduled study visits, routine diary entries, questionnaires or biomarker samples. The Investigator may arrange additional care or assessments when clinically indicated.
The primary purpose is safety and tolerability assessment. Without a concurrent control group, exploratory changes may reflect natural variability, practice effects, concomitant factors or expectation effects. They will be interpreted as hypothesis-generating observations.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Agustin Fernandez III
- Numéro de téléphone: 786-542-5499
- E-mail: AFS@advantagetherapeutics.com
Lieux d'étude
-
-
Bay Islands
-
Roatán, Bay Islands, Honduras, 34101
- Recrutement
- GARM
-
Contact:
- Heather Terry
- Numéro de téléphone: (504) 2408-3544
- E-mail: heather@garmclinic.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Subjects will only be included in the trial if they meet all following criteria:
- Written informed consent (ICF) signed and dated by the patient
- Ability and willingness to co-operate with the investigator and to comply with the requirements of the entire study.
- Healthy subjects, 35 to 85 years of age
- Sexually active females of childbearing potential and male partners of sexually active females of childbearing potential must use medically accepted form of contraception or be surgically sterile (hysterectomy or bilateral oophorectomy).
- Women of childbearing potential and men with female partners of childbearing potential must use an effective method of birth control during the course of the trial and for at least 90 days after the last dose in a manner such that risk of failure is minimized. Male participants should refrain from donating sperm during the intervention period and for at least 90 days after the last dose of study intervention (see additional considerations in section 5.3)
- Females of childbearing potential must have a negative pregnancy test at the time of enrollment (serum hCG test)
Exclusion Criteria:
Subjects will be excluded from the trial if they present one or more of the following conditions:
- Known of suspected allergy to IMP or related procedure
- Known or suspected allergy, or history of anaphylaxis, to vaccines or their excipients, if considered relevant by the Investigator
- Contraindications for the use of emergency treatments
- Clinically relevant findings at screening, e.g., active diseases of any kind particularly infections
- History of chronic alcohol or drug abuse/ dependence within the past 5 yearsUse of any prescription or over-the-counter medication within 7 days prior to first dosing or planned use during the study period, with the exception of medications considered medically necessary and administered at a stable dose and regimen. Stable medication is defined as medication for which no initiation, discontinuation, or dose adjustment has occurred for at least 3 monthsprior to first dosing and for which no change is anticipated during the study period. Occasional use of paracetamol (acetaminophen) and/or ibuprofen is permitted at the discretion of the investigator.
- Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub investigators, or study nurse) or employee of the Sponsor
- Known or suspected pregnancy, planned pregnancy of lactation
- Clinically significant unstable psychiatric illness in the past 6 months
- Presence of autoimmune disease, autoinflammatory syndrome, or immunological deficiency syndrome (including human immunodeficiency virus (HIV) infection)
- Relevant cardiovascular, hepatic, gastroenterological, respiratory, endocrinological, hematologic disease, or any other condition that, in the Investigator's opinion, could interfere with the analyses of safety and efficacy in this study, unless patient has been on stable doses of medication for any of these concurrent illnesses for at least 3 months prior to study entry
- Presence of end stage kidney failure (on dialysis)
- Current or anticipated use of immunosuppressive drugs such as, but not limited to, azathioprine, cyclosporine, methotrexate, tacrolimus, or mycophenylate within 2 months or any myelosuppressive or cytotoxic chemotherapies within the 12 months prior to the screening visit. Use of systemic corticosteroids equivalent to ≥20mg/week prednisone within the past 4 weeks before screening and during the course of the study (intranasal or inhaled steroids for allergies/asthma is allowed)
- History within the last 2 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal prostate-specific antigen posttreatment; or has a life expectancy of <2 years.
- Patients with long covid-19 showing long-term neurological sequelae within the past 12 months at the time of screening
- Has had a history within the last 5 years of a serious infectious disease affecting the brain, liver, lung and/or kidneys.
- Refractory epilepsy (has had seizures within the past 2 years)
- Hypothyroidism or vitamin B12 deficiency (patients with corrected hypothyroidism or vitamin B12 deficiency are eligible for the study provided that treatment has been stable for 3 months before study entry)
- Patient has hemochromatosis
- 19. Pre-existing anti-PEG antibodies at screening: anti-PEG IgM ≥5,000 U/mL or anti-PEG IgG ≥1,000 U/mL, as measured by the designated screening assay.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: aKLmRNA (AKL003)
Each subject will be treated every 4 weeks for a total of 2 times with aKLmRNA (AKL003) |
Each subject will be treated every 4 weeks for a total of 2 times with aKLmRNA via i.v. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall incidence and severity of unsolicited AEs by treatment group
Délai: From first dose through end of study (Day 28)
|
• To characterize the overall safety and tolerability of multiple administrations of the Investigational Medicinal product (IMP), aKLmRNA (AKL003), in healthy volunteers |
From first dose through end of study (Day 28)
|
|
• Overall incidence and severity of solicited reactogenicity events by treatment group
Délai: From first dose through end of study (Day 28)
|
• To characterize the overall safety and tolerability of multiple administrations of the Investigational Medicinal product (IMP), aKLmRNA (AKL003), in healthy volunteers |
From first dose through end of study (Day 28)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
• Increase in serum aKL levels over the mean of the baseline values until end of study
Délai: Baseline through Day 28
|
• To characterize the serum levels of aKL protein as a function of the dose applied and time post administration. |
Baseline through Day 28
|
|
• aKL serum level by treatment group
Délai: Baseline through Day 28
|
• To characterize the serum levels of aKL protein as a function of the dose applied and time post administration. |
Baseline through Day 28
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
• Change from baseline to day 60 in episodic memory performance measrued by Face-Name Associative Memory Exam
Délai: Baseline through Day 28
|
• To characterize the clinical activity after multiple administrations of aKLmRNA AKL003 |
Baseline through Day 28
|
|
• Change from baseline to day 60 in attention and inhibitory control measured Flanker Test
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in working memory performance measured by NIH Toolbox List Sorting Working Memory Test
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in processing speed assessed by Oral Symbol Digit Test
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in reaction time using digital repeated measures
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function, |
Baseline through Day 28
|
|
• Change from baseline in selected standardized neuropsychological assessments aligned with established cognitive testing platforms (CANTAB-based measures)
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, including cognitive function, |
Baseline through Day 28
|
|
• Change from baseline to day 60 in grip strength measured by a hand dynamometer
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in functional exercise capacity assessed by6 -minute walk test
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in lower body functional performance assessed by chair-rise or comparable assessment
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, physical (muscle) function |
Baseline through Day 28
|
|
• Change from baseline to day 60 in NAD+ levels measured in serum
Délai: Baseline through Day 28
|
• To explore the effects of aKLmRNA administration on functional and biological domains relevant to aging and healthspan, i immune/inflammatory function |
Baseline through Day 28
|
|
Change from baseline in telomere length (T/S ratio) in peripheral blood mononuclear cells (PBMCs), as measured by quantitative PCR (qPCR), at Day 60
Délai: Baseline through Day 28
|
Baseline through Day 28
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Douglas A Tucker, MD, GARM
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- AKL003
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .